---

Early Cancer Detection Matters

Although cancer can be a scary diagnosis, several types of cancer are fully treatable. Outcomes are especially improved when cancer is found in the early stages. Unfortunately 50% of cancers are still found in the later stages (1). 

​Aristotle® is a new blood test that can detect the molecular signatures of multiple cancers from a single sample of blood to help you find cancer earlier. ​​

Why Early Is Better

A late stage cancer diagnosis can be attributed to many factors such as postponing cancer screening, symptoms often don't appear until cancer has progressed or a lack of convenient screening options. The chart below demonstrates the importance of early detection. Contact us to find out if the Aristotle blood test is right for you.

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.

Our Science

• Aristotle looks for the molecular signatures multiple cancers through a blood sample. (3)
• Our Underlying  mRNA technology, The Sentinel Principle has been validated in more than 9,000 patients and used by more than 100,000 patients in North America. (3) 
• Aristotle was selected for online publication at the 2020 annual meeting of the American Society of Clinical Oncology (ASCO). ​​​

​

Our Laboratory

Our laboratory in Richmond, VA is certified according to the Clinical Laboratory Improvement Amendment (CLIA) for high complexity laboratory testing through the Centers of Medicare and Medicaid Services (CMS). In addition, the lab is accredited through the College of American Pathologists (CAP). These certifications demonstrate our highest commitment to excellence in laboratory test processing and our passion for patient care. 
​

​

Sources:
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.
2. American Institute of Cancer Research (AICR.org) accessed January 2022.
3. Aristotle: A single blood test for pan-cancer screening.Adam A Dempsey, Samuel Chao, Dimitri Stamatiou, Tanya Pilcz, Jay Ying, and Robert Burakoff; Journal of Clinical Oncology 2020 38:15_suppl, e15037-e15037
​
Aristotle® was developed and its performance characteristics determined by Stage Zero Life Sciences, Inc.  It has not been cleared or approved by the US Food and Drug Administration. This test is performed in a CLIA certified laboratory and is intended for clinical purposes. The ARISTOTLE® test must be ordered by and used only in consultation with a healthcare provider.



 
​